Bavarian Nordic to Host Full Year 2010 Conference Call

KVISTGÅRD, Denmark - March 8, 2011 - Bavarian Nordic A/S (NASDAQ OMX:  BAVA) announces its 2010 full year results on Thursday, March 10. The company will host two conference calls on the same day at 9 a.m. (CET) and again at 4 p.m. (CET). A short presentation will be held by President and CEO, Anders Hedegaard, followed by a Q&A session. Also attending are Reiner Laus, EVP & Division President Cancer Vaccines, Ole Larsen, EVP & CFO and Rolf Sass Sørensen, VP Investor Relations & Communications. Dial-in numbers for the conference call are:  Denmark: +45 32 71 46 07, UK: +44 (0)20 7162 0077, US: +1 334 323 6201. For additional countries and further details please visit where also the accompanying presentation will be available in advance of the conference call. Contact Rolf Sass Sørensen, Vice President Investor Relations & Communications. E-mail: Phone: +45 33 26 83 83 About Bavarian Nordic Bavarian Nordic is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's clinical pipeline targets cancer and infectious diseases, and includes seven development programmes. Two programmes under preparation for Phase 3: PROSTVAC®, a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute, and IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract with the US government. Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA. For more information please visit This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Thomson Reuters ONE [HUG#1495444]